To inquire about our available technologies, call our office (813) 745-6828

Name & Description Number
HER-2: Combination Therapy of a HER2-DC1 Dendritic Cell Cancer Vaccine and a Probiotic 20MA016N
TILs: 12 Chemokine Gene Expression Signature to Increase the Efficacy of Manufacturing Tumor Infiltrating Lymphocytes 20MA013N
PERK, IRE1: Method of Enhancing Immunotherapy Using ER Stress Pathway Inhibitors 20MA005N
PGC-1α: CAR-T Cells with Enhanced Metabolic Fitness due to Co-expression of Mutant PGC-1α 19MB066
Antibodies: Fully Human anti-BDNF Antibodies 19MB048N
Antibodies: Fully Human anti-TSPAN7 Antibodies 19MB047N
T-bet: T-bet Transcription Factor Armed CAR-T Cells Maintain Memory Phenotypes and Rescue CD4 Cells Leading to Increased Persistence 19MA035N
EGFR, MUC1: Bispecific CAR-T Cell constructs (chimeric antigen receptors) that Recognize EGFR and MUC1 for the Treatment of Lung Cancer 19MA033N
Bispecific T-Cell Engagers: B Cells Engineered to Express Bispecific T-Cell Engagers Result in Longer Half Lives 19MA029N
NOTCH: Enhancing the Efficacy of Adoptive T-cell Immunotherapy Using Novel Notch Ligands 19MA026N
aAPC: Artificial Antigen-Presenting Cells Expressing NKG2D Ligands for Producing anti-NKG2D CAR-T Cells 19MA022N
NKG2D-Ligand: Enhancing Carcinoma Infiltration by NKG2D-Ligand Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1 19MA015NT2
GPC3: Enhancing Carcinoma Infiltration by Anti-GPC3 Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1 19MA015N
B-RAF: Combination Therapy of TILs and BRAF Inhibitors to Treat BRAF Inhibitor-Resistant Metastatic Melanoma 19MA007
TILs: Enhancing the anti-tumor immunity of TILs by inhibiting Sirt2 18MB078
Antibodies: Fully Human anti-LAG3 Antibodies 18MB062N
Antibodies: Fully Human anti-PD1 Antibodies 18MB061
Brain Mets: Lung Cancer Brain Metastases Targeting CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers 18MB059
Suicide Switch: CAR-T cells can be Designed to Self-Destruct if Patient shows signs of Toxicity including graft-vs.-host-disease, cytokine release syndrome (CRS), and neurotoxicty 18MB049N
TLR9 Ligand Trap: TLR9-IgG4 Fusion Protein to Neutralize Innate Immune Activation and Chronic Inflammation Contributing to MDS Pathogenesis 18MB048N
Inflammasome: Method of Using Small-molecule Pyrin-domain Targeted NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis 18MB044N
PSCA: Targeting Gamma Delta CAR-T Cells for the Treatment of Bone Metastatic Castrate-Resistant Prostate Cancer 18MA037
TILs: Method of Using a Demethylating Agent to Enhance STING Expression and TIL Anti-Tumor Activity in Melanoma 18MA034N
TILs: TILs modified with CAR constructs result in CAR-TILs for Cancer Therapy 18MA033
AaPC: Artificial Antigen-Presenting Cells with Heparin-Binding Domain and Protein L for Producing CAR-T Cells 18MA019N
CD83: Targeting CAR-T cells Protect “Off the Shelf” Allogeneic CAR-T cells from Rejection 18MA007T2
TILs: The Use of Fucose to Increase TILs for the Immunotherapy of Melanoma 17MB048
Inflammasome: Stapled Peptides NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis 17MB037
CD123: CAR-T Cell Constructs that Recognize CD123 for the Treatment of Acute Myeloid Leukemia 17MA031
CD33, CD123: Bispecific CAR-T Cell Constructs that Recognize CD33 and CD123 for the Treatment of Acute Myeloid Leukemia 17MA030T2
CD33: CAR-T Cell Constructs that Recognize CD33 for the Treatment of Acute Myeloid Leukemia 17MA030
TILs: Simple and Rapid Method for Culture of TILs from Melanoma Tumor Fragments or Core Needle Biopsies of Solid Tumors 17MA012
CD3-CD28: Bispecific Antibody for the Generation of CAR-T cells for Cancer Immunotherapy 17MA007
IL-13Rα2: Targeting Chimeric Antigen Receptor Expressing T cell (CAR-T) for Melanoma Immunotherapy 16MB069
TAG72: Targeting Chimeric Antigen Receptor Expressing T cell (CAR-T) for Cancer Immunotherapy 16MB057
AaPC: Artificial Antigen-Presenting Cells for Expanding TILs and MILs in Cancer Immunotherapy 16MB050
aAPC: Artificial Antigen-Presenting Cells expressing CD3, CD28 and a Heparin-Binding Domain for Producing CAR-Ts 16MB049
TLS: Method of Using Chitosan Hydrogels with Chemokine-Releasing Microparticles or Stromal Cells to Bioengineer Tertiary Lymphoid Structures to Enhance the Immune System for Cancer Therapy 16MA028N
TLR9: Targeting Chimeric Antigen Receptor-Expressing T cell (CAR-T) for MDS and AML Immunotherapy 16MA025
NLRP3 Inflammasome: Small Molecule Oral Signaling Inhibitor Icaritin Analog to Improve Hematopoiesis by Inhibiting NLRP3 Inflammasome Activation in MDS 16MA006N
TIM3 Ligand Trap: TIM-3-IgG4 Fusion Protein for the Treatment of Anemia in Low- or Intermediate (Int)-risk MDS Patients 16MA001
Cancer Vaccine: Full-Length Variant Survivin Vaccine Potentiates Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma 14MB098
TAG72-CD3: Bispecific T-cell Engager Antibody for Targeted Cancer Immunotherapy 14MB072
HDAC6: Method of Using Histone Deacetylase 6 Inhibition for Enhancing T cell Function During Anti-Tumor Response and Tumor-Peptide Vaccination 14MA037N
HDAC: Method of Using Histone Deacetylase as a Modulator of PDL1 Expression and Activity 14MA027N
S100A9: CD33/IgG1 Chimera Antibody Trap to Neutralize S100A9 to Treat MDS 13MB041
Vaccine: Vaccines Using Synthetic Peptide-Poly IC Complexes that Elicit T-cell Responses Comparable to Live Vaccination 11MA013
Antibodies: Use of Antibodies to MARCO for Enhanced Dendritic Cell Vaccine Efficacy 07MB004